Please assess the completion status of the following clinical trial:

Trial Title: Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged 18 to 65 years with a confirmed diagnosis of UC.~2. Diagnosis of UC established at least 6 months before enrollment or evidence of chronicity in colonic biopsies.~3. Patients with UC disease extent beyond 15 cm (must involve at least the sigmoid colon)~4. In female patients:~   * Post-menopausal for ≥1 year before screening, or~  * Surgically sterile, or~  * Agree to be on a contraceptive method from the screening visit through 4 weeks after discontinuing tacrolimus (or placebo), or~  * Completely abstain from heterosexual intercourse.~5. In male patients:~   o Agreement not to father a child through 4 weeks after discontinuing tacrolimus (through contraception or abstinence).~6. Moderate to severe UC~   * Mayo Clinic partial UC score of 6 to 12, with a baseline sigmoidoscopy sub-score of at least 2, and disease that extended 15 cm or more from the anal verge.~  * Steroid dependent patients (Appendix 1)~  * Steroid naïve or steroid responsive~7. Patients are planned to start vedolizumab as part of their clinical care.~8. 5-aminosalicilates (oral or topical) are permitted as long as the dose is stable for at least 2 weeks before screening.~9. Patients with or without previous exposure to anti-TNF agents can be included. Patients with previous exposure to anti-TNF must be off infliximab for 8 weeks and off adalimumab for 4 weeks.~10. Anti-diarrheals (eg, loperamide, diphenoxylate with atropine) for control of chronic diarrhea are not permitted.The patient must be off anti-diarrheal at the time of screening.~11. Immunosupressants (thiopurines or methotrexate) must be stopped 4 weeks prior to starting the study medications.~12. Patients with previous Clostridium Difficile infection can be included as long as they received a full course of therapy and have a negative Clostridium Difficile PCR test and are infection free for 60 days prior to screening.~Exclusion Criteria:~1. Positive stool test for parasites or stool culture for pathologic bacteria within 30 days prior to enrollment.~2. Evidence or history of Clostridium Difficile infection within 60 days prior to enrollment.~3. Active Cytomegalovirus (CMV) infection evidenced by a positive CMV PCR in serum and/or positive immunohistochemistry stain in colonic tissue.~4. Uncontrolled hypertension.~5. Chronic kidney disease (defined as a glomerular filtration rate \< 60 mL/min, calculated using the Modification of Diet in Renal Disease (MDRD) formula)~6. Chronic liver disease.~7. A refractory electrolyte disorder (e.g. hypomagnesemia).~8. Persistent hypomagnesemia that does not respond to oral magnesium supplementation defined as a value \<1.3 mEq/L in two separate readings, despite the administration of oral magnesium \[10 meq of slow-release magnesium chloride three times per day for 48 hours\].~9. Persistent hypophosphatemia defined as levels \<2.2 mg/dL in two separate readings, 48 hours apart despite phosphate supplementation (sodium phosphate/potassium phosphate 500 mg up to three times daily for 48 hours).~10. Creatinine values of 1.5 mg/dL in 2 separate readings.~11. Established diagnosis of diabetes mellitus.~12. Clinical or radiological evidence of megacolon.~13. Intestinal perforation, or abdominal abscess within 3 months prior to enrollment.~14. Active clinically significant bacterial infection (within 30 days of enrollment).~15. Personal history of total or sub-total colectomy.~16. Current Pregnancy or lactation.~17. Unstable or uncontrolled medical disorder.~18. Personal history of malignant neoplasm.~19. Inability to give informed consent.~20. History of alcohol or illicit drug abuse in the previous 6 months to enrollment.~21. Patient that have received any experimental drug within 6 months prior to enrollment.~22. Patients with previous exposure to vedolizumab, cyclosporine or tacrolimus.~23. Personal history of congenital or acquired immunodeficiency (eg, common variable immunodeficiency, human immunodeficiency virus \[HIV\] infection, organ transplantation) excluding pharmacologic immunosuppressant.~24. Any of the following laboratory abnormalities during the screening period:~    1. Hemoglobin level \<9 g/dL~   2. WBC count \<3 × 109/L~   3. Lymphocyte count \<0.5 × 109/L~   4. Platelet count \<100 × 109/L or \>1200 × 109/L~   5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2 × the upper limit of normal (ULN)~25. To avoid interactions, patients on medications that induce or inhibit the Cytochrome p450 family 3, subfamily A (CYP3A) will be excluded. CYP3A inducers and inhibitors are shown in Appendix 3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: ACTIVE_COMPARATOR): vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
- Placebo Arm (Type: PLACEBO_COMPARATOR): vedolizumab at standard regimen with placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).